RUNX3 regulates the susceptibility against EGFR-targeted non-small cell lung cancer therapy using Sc-conjugated cetuximab.

Background: Radioimmunotherapy with cetuximab and conjugates with various radioisotopes is a feasible treatment option for different tumor models. Scandium-47 (Sc), one of several β-particle-emitting radioisotopes, displays favorable physical and chemical properties for conjugation to monoclonal antibodies. However, the therapeutic efficacy of Sc in preclinical and clinical studies is largely unknown.

Lu-177 preparation for radiotherapy application.

A separation study using a (176)Yb target for the preparation of nca (177)Lu, which is a beta-emitting nuclide used not only in radioimmunotherapy applications but also in the treatment of various lesions, has been performed. A material having a better selectivity and separation efficiency for Lu than Yb was developed, and the separation conditions of (177)Lu were derived using this from a neutron irradiated (176)Yb target. The separation material was an organo-ceramic hybrid material containing a phosphate group.

Preclinical pharmacokinetic, biodistribution, imaging and therapeutic efficacy of (177)Lu-Labeled glycated bombesin analogue for gastrin-releasing peptide receptor-positive prostate tumor targeting.

Unlabelled: The gastrin-releasing peptide receptor (GRPR) has been shown to be overexpressed in many human tumors, including prostate, colon, gastric, breast, pancreatic, and small cell lung cancers. Because bombesin (BBS) binds to GRPR with high affinity, BBS derivatives have been labeled with various radionuclides and have been demonstrated to be successful candidates for peptide receptor radiotherapy (PRRT). The present study describes the in vitro and in vivo preclinical characteristics of (177)Lu-DOTA-Lys(glucose)-4 aminobenzoic acid-BBS7-14 ((177)Lu-DOTA-gluBBN) to prepare radiolabeled candidates for the treatment of GRPR-expressing prostate tumors.

Biological evaluation of (177)Lu-labeled DOTA-Ala(SO3H)-Aminooctanoyl-Gln-Trp-Ala-Val-N methyl Gly-His-Statine-Leu-NH2 for gastrin-releasing peptide receptor-positive prostate tumor targeting.

Bombesin binds with selectivity and high affinity to a Gastrin-releasing peptide receptor (GRPR), which is highly overexpressed in prostate cancer cells. The present study describes the in vitro and in vivo biological characteristics of DOTA-Ala(SO3H)-Aminooctanoyl-Gln-Trp-Ala-Val-N methyl Gly-His-Statine-Leu-NH2 (DOTA-sBBNA), an antagonist analogue of bombesin peptide for the targeting of GRPR. DOTA-sBBNA was synthesized and labeled with (177)Lu as previously published.

Dosimetry of a new P-32 ophthalmic applicator.

Purpose: The potential of P-32 ophthalmic applicator irradiation after pterygium excision has been demonstrated as an alternative to Sr∕Y-90 irradiation. This study aimed to provide the clinical dosimetry for this new applicator.

Methods: The prototype of a cylindrical P-32 applicator was fabricated according to the Monte Carlo (MC)-based design study.

One column operation for (90)Sr/(90)Y separation by using a functionalized-silica.

Organo-ceramic hybrid materials have been developed as the separation media for a (90)Sr/(90)Y generator system. Currently available (90)Y is generally extracted from a mother solution by a solvent extraction or a successive column operation. Both processes are successfully applied to produce (90)Y with a high quality standard.

Development of a high performance (188)W/(188)Re generator by using a synthetic alumina.

A synthetic alumina functionalized with a sulfate moiety has been developed as the column material of (99)Mo/(99m)Tc and (188)W/(188)Re generators. This material is synthesized by a sol-gel processing. In order to characterize the adsorbent for the (188)W/(188)Re separation, both batch and column contact experiments were conducted.

Potential use of P-32 ophthalmic applicator: Monte Carlo simulations for design and dosimetry.

Postoperative beta-irradiation after pterygium excision has been considered a valuable therapeutic procedure to reduce the recurrence rate. Recently, it was reported that beta-irradiation also substantially reduced the risk of surgical failure after glaucoma surgery. Pure beta-irradiation using a 90Sr/Y applicator has been almost exclusively used for this purpose.

Gene cloning, sequencing, and expression of an esterase from Acinetobacter lwoffii I6C-1.

The esterase-encoding gene, estA, was cloned from Acinetobacter lwoffii I6C-1 genomic DNA into Escherichia coli BL21(DE3) with plasmid vector pET-22b (pEM1). pEM1 has a 4.4-kb EcoRI insert that contained the complete estA gene.